Role of the preliminary susceptibility testing for initial and after failed therapy of Helicobacter pylori infection with levofloxacin, amoxicillin, and esomeprazole

Helicobacter

Volumn 11, Issue 4, 2006, Pages 237-242

  Marzio, Leonardo ^a,b   Coraggio, Daniela ^a   Capodicasa, Simona ^a   Grossi, Laurino ^a   Cappello, Giorgio ^a  

^a UNIVERSITY OF CHIETI   (Italy)

^b Ospedale Civile di Pescara   (Italy)

Author keywords

H. pylori; Levoflaxacin; Primary resistance; Secondary resistance; Susceptibility test

Indexed keywords

AMOXICILLIN; CARBON 13; CLARITHROMYCIN; ESOMEPRAZOLE; LEVOFLOXACIN; RIFABUTIN; TINIDAZOLE;

ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SCREENING; DRUG TREATMENT FAILURE; DYSPEPSIA; EMPIRICISM; ERADICATION THERAPY; FEMALE; GASTROINTESTINAL ENDOSCOPY; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT INDICATION; UREA BREATH TEST;

ADULT; AMOXICILLIN; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BREATH TESTS; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; ENDOSCOPY, DIGESTIVE SYSTEM; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; OFLOXACIN; OMEPRAZOLE; TREATMENT OUTCOME; UREASE;

HELICOBACTER PYLORI;

EID: 33745922076     PISSN: 10834389     EISSN: 15235378     Source Type: Journal    
DOI: 10.1111/j.1523-5378.2006.00407.x     Document Type: Article

References (29)

1. Guslandi M. Review article: alternative antibacterial agents for Helicobacter pylori eradication. Aliment Pharmacol Ther 2001;15:1543-7.
2. Shimoyama T, Fukuda S, Mikami T, Fukushi M, Munakata A. Efficacy of metronidazole for the treatment of clarithromycin-resistant Helicobacter pylori infection in a Japanese population. J Gastroenterol 2004;39:927-30.
3. Romano M, Marmo R, Cuomo A, et al. Pretreatment antimicrobial susceptibility testing is cost saving in the eradication of Helicobacter pylori. Clin Gastroenterol Hepatol 2003;1:273-8.
4. The European Helicobacter pylori Study Group (EHPSG). Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus report. Gut 1997;41:8-13.
5. National Institutes of Health. NIH Consensus Conference. Helicobacter pylori in peptic ulcer disease. JAMA 1994;272:65-9.
6. Watanabe Y, Aoyama N, Shirasaka D, et al. Levofloxacin based triple therapy as a second-line treatment after failure of Helicobacter pylori eradication with standard triple therapy. Dig Liver Dis 2003;35:711-5.
7. Talley NJ, Vakil N. Practice Parameters Committee of the American College of Gastroenterology. Guidelines for the management of dyspepsia. Am J Gastroenterol 2005;100:2324-37.
8. Toracchio S, Marzio L. Primary and secondary antibiotic resistance of Helicobacter pylori strains isolated in central Italy during the years 1998-2002. Dig Liver Dis 2003;35:541-5.
9. National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Susceptibility Testing - Fourth Information Supplement. Document M100-S4. NCCLS, Villanova, PA, 1992.
10. Cellini L, Grande R, Di Campli E, Di Bartolomeo S, Capodicasa S, Marzio L. Analysis of genetic variability, antimicrobial susceptibility and virulence markers in Helicobacter pylori identified in Central Italy. Scand J Gastroenterol 2005;40:1-8.
11. Debets-Ossenkopp YJ, Herscheid AJ, Pot RG, Kuipers EJ, Kusters JG, Vandenbroucke-Grauls CM. Prevalence of Helicobacter pylori resistance to metronidazole, clarithromycin, amoxycillin, tetracycline and trovafloxacin in The Netherlands. J Antimicrob Chemother 1999;43:511-5.
12. Sharara AI, Chedid M, Araj GF, Barada KA, Mourad FH. Prevalence of Helicobacter pylori resistance to metronidazole, clarithromycin, amoxycillin and tetracycline in Lebanon. Int J Antimicrob Agents 2002;19:155-8.
13. Lee MG, Arthurs M, Smikle MF, Dowe G, Levy V, Barton EN. Antibiotic sensitivity of Helicobacter pylori in Jamaica. West Indian Med J, 2004;53:374-7.
14. Toracchio S, Capodicasa S, Soraja DB, Cellini L, Marzio L. Rifabutin based triple therapy for eradication of H. pylori primary and secondary resistant to tinidazole and clarithromycin. Dig Liver Dis 2005;37:33-8.
15. Watanabe K, Tanaka A, Imase K, et al. Amoxicillin resistance in Helicobacter pylori: studies from Tokyo, Japan from 1985 to 2003. Helicobacter 2005;10:4-11.
16. Perri F, Festa V, Clemente R, et al. Randomized study of two 'rescue' therapies for Helicobacter pylori-infected patients after failure of standard triple therapies. Am J Gastroenterol 2001;96:58-62.
17. Cammarota G, Martino A, Pirozzi G, et al. High efficacy of 1-week doxycycline- and amoxicillin-based quadruple regimen in a culture-guided, third-line treatment approach for Helicobacter pylori infection. Aliment Pharmacol Ther 2004;19:789-95.
18. Toro C, Garcia-Samaniego J, Carbo J, et al. Prevalence of primary Helicobacter pylori resistance to eight antimicrobial agents in a hospital in Madrid. Rev Esp Quimioter 2001;14:172-6.
19. Heep M, Kist M, Strobel S, Beck D, Lehn N. Secondary resistance among 554 isolates of Helicobacter pylori after failure of therapy. Eur J Clin Microbiol Infect Dis 2000;19:538-41.
20. Branca G, Spanu T, Cammarota G, et al. High levels of dual resistance to clarithromycin and metronidazole and in vitro activity of levofloxacin against Helicobacter pylori isolates from patients after failure of therapy. Int J Antimicrob Agents 2004;24:433-8.
21. Megraud F, Lamouliatte H. Review article: the treatment of refractory Helicobacter pylori infection. Aliment Pharmacol Ther 2003;17:1333-43.
22. Iwao E, Yokoyama Y, Yamamoto K, Hirayama F, Haga K. In vitro and in vivo anti-Helicobacter pylori activity of Y-904, a new fluoroquinolone. J Infect Chemother 2003;9:165-71.
23. Bilardi C, Dulbecco P, Zentilin P, et al. A 10-day levofloxacin-based therapy in patients with resistant Helicobacter pylori infection: a controlled trial. Clin Gastroenterol Hepatol 2004;2:997-1002.
24. Perri F, Festa V, Merla A, Barberani F, Pilotto A, Andriulli A. Randomized study of different 'second-line' therapies for Helicobacter pylori infection after failure of the standard 'Maastricht triple therapy.' Aliment Pharmacol Ther 2003;18:815-20.
25. Nista EC, Candelli M, Cremonini F, et al. Levofloxacin-based triple therapy vs. quadruple therapy in second-line Helicobacter pylori treatment: a randomized trial. Aliment Pharmacol Ther 2003;18:627-33.
26. Coelho LG, Moretzsohn LD, Vieira WL, et al. New once-daily, highly effective rescue triple therapy after multiple Helicobacter pylori treatment failures: a pilot study. Aliment Pharmacol Ther 2005;21:783-7.
27. Zullo A, Hassan C, Campo SM, et al. A triple therapy regimen after failed Helicobacter pylori treatments. Aliment Pharmacol Ther 2001;15:1193-7.
28. Zullo A, Hassan C, De Francesco V, et al. A third-line levofloxacin-based rescue therapy for Helicobacter pylori eradication. Dig Liver Dis 2003;35:232-6.
29. Gatta L, Zullo A, Perna F, et al. A 10-day levofloxacin-based triple therapy in patients who have failed two eradication courses. Aliment Pharmacol Ther 2005;22:45-9.